NCT02448368 - RDEA3170 Tablet and Capsule Bioavailability Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

June 26, 2015

Study Completion Date

January 29, 2016

Conditions

Healthy

Interventions

DRUG

RDEA3170,10 mg

Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

DRUG

RDEA3170, 2.5 mg

Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

DRUG

RDEA3170, 5 mg

Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

DRUG

RDEA3170, 10 mg

Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.

DRUG

RDEA3170, 2.5 mg

Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.

Trial Locations (1)

Austin